Insulin Tolerance Test (ITT)

The graph above illustrates the blood glucose changes of mice with different treatments responding to an exogenous insulin challenge. All mice were fasted for 4 hours before the test. During ITT assay, mice were measured for blood glucose at 0 min (baseline), 15min, 45min and 90min post-insulin challenge. All mice were administered with an insulin solution (0.8U/kg) via S.C. injection. (A) Compared to the mice of control diet-Vehicle, mice of High-fat Diet (HFD)-Vehicle displayed a profound whole-body insulin resistance, indicating by the significantly higher blood glucose at timepoints of 0 min (baseline), 15min and 45min post-insulin injection. Compared with HFD-vehicle mice, the HFD-MLR1023 mice significantly improved insulin sensitivity, which is reflected by significantly decreased blood glucose at timepoints of -30min (baseline), 15min and 45min post-insulin injection. (B) The area under curve (AUC) were also calculated based on the glucose levels of each time point. Compared to control diet-Vehicle, the AUC value was significantly higher in HFD-Vehicle group. MLR1023 treatment markedly reduced the AUC values, which induced by HFD feeding. Data are mean±SEM and analyzed by Unpaired T-tests as applicable (*p<0.05,**p<0.01, vs. HFD-Vehicle; #p<0.05, ###p<0.001, vs. Control diet-Vehicle) (N=7-11).

MLR-1023 is a potential “next-generation” insulin sensitizer that works independently of a PPAR mechanism by activating Lyn kinase. For more information on MLR-1023, please visit our sister site, Melior Pharmaceuticals.